Abcellera Biologics Inc
ABCL3.160USD
+0.380+13.67%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
944.88MCap. mercado
PérdidaP/E TTM
Más Datos de Abcellera Biologics Inc Compañía
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Información de Abcellera Biologics Inc
Símbolo de cotizaciónABCL
Nombre de la empresaAbcellera Biologics Inc
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoHansen (Carl L.G)
Número de empleados596
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 11
Dirección150 W 4Th Avenue
CiudadVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV5Y 1G6
Teléfono16045599005
Sitio Webhttps://www.abcellera.com/
Símbolo de cotizaciónABCL
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoHansen (Carl L.G)
Ejecutivos de Abcellera Biologics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen Quake
Mr. Stephen Quake
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2024Q2
FY2023Q2
Por negocioUSD
Nombre
Ganancia
Proporción
Research fees
8.82M
98.46%
Licensing revenue
138.00K
1.54%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Research fees
8.82M
98.46%
Licensing revenue
138.00K
1.54%
Estadísticas de accionistas
Actualizado: dom., 25 de ene
Actualizado: dom., 25 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Thermopylae Holdings Ltd
18.68%
Baker Bros. Advisors LP
9.20%
Capital World Investors
4.46%
Two Sigma Investments, LP
3.34%
Lecault (Veronique)
3.21%
Otro
61.11%
Accionistas
Accionistas
Proporción
Thermopylae Holdings Ltd
18.68%
Baker Bros. Advisors LP
9.20%
Capital World Investors
4.46%
Two Sigma Investments, LP
3.34%
Lecault (Veronique)
3.21%
Otro
61.11%
Tipos de accionistas
Accionistas
Proporción
Corporation
18.68%
Hedge Fund
16.25%
Investment Advisor
9.45%
Individual Investor
4.29%
Investment Advisor/Hedge Fund
3.93%
Research Firm
2.06%
Bank and Trust
0.69%
Pension Fund
0.29%
Sovereign Wealth Fund
0.21%
Otro
44.14%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
320
98.53M
32.92%
-53.59M
2025Q3
340
112.51M
51.75%
-3.28M
2025Q2
368
115.12M
53.94%
-18.45M
2025Q1
420
133.63M
52.62%
-23.37M
2024Q4
441
121.95M
50.14%
+4.83M
2024Q3
440
121.95M
51.59%
-4.54M
2024Q2
439
127.07M
51.27%
-6.55M
2024Q1
432
134.44M
53.43%
-22.43M
2023Q4
425
138.44M
60.93%
-1.40M
2023Q3
426
134.18M
60.12%
-4.59M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Thermopylae Holdings Ltd
55.92M
18.68%
-225.00K
-0.40%
Dec 18, 2025
Baker Bros. Advisors LP
27.53M
9.2%
--
--
Sep 30, 2025
Capital World Investors
13.36M
4.46%
--
--
Sep 30, 2025
Two Sigma Investments, LP
9.99M
3.34%
+1.81M
+22.09%
Sep 30, 2025
Lecault (Veronique)
9.61M
3.21%
--
--
Apr 01, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.37%
--
--
Sep 30, 2025
Renaissance Technologies LLC
3.36M
1.12%
+53.30K
+1.61%
Sep 30, 2025
Tang Capital Management, LLC
2.60M
0.87%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
2.56M
0.85%
+1.79M
+234.13%
Sep 30, 2025
Millennium Management LLC
2.43M
0.81%
-967.85K
-28.49%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Genomics Immunology and Healthcare ETF
2.64%
Virtus LifeSci Biotech Clinical Trials ETF
1.19%
ProShares Ultra Nasdaq Biotechnology
0.16%
Invesco Nasdaq Biotechnology ETF
0.16%
SPDR S&P International Small Cap ETF
0.12%
iShares Biotechnology ETF
0.11%
Invesco RAFI Developed Mkts ex-US SM ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Ver más
iShares Genomics Immunology and Healthcare ETF
Proporción2.64%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.19%
ProShares Ultra Nasdaq Biotechnology
Proporción0.16%
Invesco Nasdaq Biotechnology ETF
Proporción0.16%
SPDR S&P International Small Cap ETF
Proporción0.12%
iShares Biotechnology ETF
Proporción0.11%
Invesco RAFI Developed Mkts ex-US SM ETF
Proporción0.05%
Avantis US Small Cap Equity ETF
Proporción0.01%
SPDR Portfolio Developed World ex-US ETF
Proporción0.01%
Fidelity Nasdaq Composite Index ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
